Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/36—Blood coagulation or fibrinolysis factors
  • A61K38/366—Thrombomodulin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to novel strategies for increasing the reperfusion in obstructed blood vessels and claims priority of the European patent application 07 013 480.4, European patent application 08 009 096.2 and European patent application 08 010 333.6 which are hereby fully incorporated in terms of disclosure.
• ischemia a thrombus formation in a blood vessel.
• Ischemia is inter alia a feature of certain heart diseases, transient ischemic attacks, cerebrovascular accidents, rupture of arteriovenous malformations and/or peripheral artery occlusive diseases. Tissues especially sensitive to inadequate blood supply include the heart, the kidneys and the brain. Ischemia in brain tissue, for example due to a stroke or head injury, causes the so-called ischemic cascade to be unleashed, which stands for a series of consecutive, parallel and interacting biochemical events involving proteolytic enzymes, reactive oxygen species, and other active compounds. The final outcome of this sequence is damage and destruction of brain tissue. Stroke, a synonym for ischemic events in brain tissue, is the third leading cause of death, after cardiovascular disease and cancer. Each year, stroke is diagnosed in 750.000 patients and contributes to nearly 168.000 deaths in the United States only. Stroke has a high personnel and social impact because of the severe disability that the disease causes.
• Recanalization of occluded arteries to restore blood supply is the most effective therapy for stroke treatment in humans to date.
• the success rate of such treatment is reduced by the possibilities of intracerebral hemorrhage and reocclusion.
• Hemorrhage is part of the damage caused by the ischemic cascade, but is also a risk associated with thrombolytic agents.
• Reocclusion may occur at the same site or by fragments of the original clot that have been carried downstream.
• a known method for prevention of obstruction or reobstruction (reocclusion) of vessels is to treat a thrombotic patient with an anticoagulant or antiplatelet drug.
• Anticoagulants are substances, which reduce the ability of blood to form blood clots.
• Various anticoagulants are known to the skilled person, for example heparin or warfarin.
• urgent anticoagulation with the goal of preventing early recurrent stroke, halting neurological worsening, or improving outcomes after acute stroke is not recommend for treatment of patients with acute ischemic stroke
• urgent anticoagulation is not recommend for patients with moderate and severe strokes because of an increased risk of serious intracranial hemorrhagic complications
• thrombomodulin can be used to improve or even effect reperfusion of obstructed blood vessels, in particular obstructed blood vessels of stroke patients. This improvement is linked to an substantial increase in the risk of hemorrhagic transformation. Due to this reperfusive activity thrombomodulin can be clinically used as a thrombolytic.
• a thrombolytic is a substance that directly or indirectly removes or reduces an occlusion and thereby leads to reperfusion of a blood vessel. Besides this thrombolytic (or profibrinolytic) properties thrombomodulin exhibits - as already known - anticoagula- tive properties.
• Thromboembolic events which can be treated with thrombomodulin as a thrombolytic includes, but is not limited to, myocardial infarction, deep vein thrombosis, pulmonary embolism, portal or renal vein thrombosis, hepatic thrombosis (Budd-Chiari syndrome), thrombosis of the upper extremities (Paget-Schroetter disease), or thoracic outlet syndrome as well as stroke events.
• Thrombomodulin is a membrane protein that acts as a thrombin receptor on the endothelial cells lining the blood vessels.
• Thrombin is a central enzyme in the coagulation cascade, which converts fibrinogen to fibrin, the matrix clots are made of. Initially, a local injury leads to the generation of small amounts of thrombin from its inactive precursor, prothrombin. Thrombin, in turn, activates platelets and, second, certain coagulation factors including factors V and VIII. The latter action gives rise to the so-called thrombin burst, a massive activation of additional thrombin molecules, which finally results in the formation of a stable clot.
• a major feature of the thrombin-thrombomodulin complex is its ability to activate protein C, which then downregulates the coagulation cascade by proteolytically inactivating the essential cofactors Factor Va and Factor Villa (Esmon et al., Ann. N. Y. Acad. Sci. (1991), 614:30-43), thus affording anticoagulant activity.
• the thrombin- thrombomodulin complex is also able to activate the thrombin-activatable fibrinolysis inhibitor (TAFI), which then antagonizes fibrinolysis.
• TAFI thrombin-activatable fibrinolysis inhibitor
• thrombomodulin is not only present in brain endothelial cells (Boffa, et al., Nouv. Rev. Fr. Hematol. (1991), 33:423-9; Wong, et al., Brain Res. (1991), 556:1-5; Wang, et al., Arte- rioscler. Thromb. Vase. Biol.
• Thrombomodulin is also upregu- lated in reactive astrocytes in the CNS, in response to mechanical injury (Pindon, et al., J. Neurosci. (2000), 20:2543-50).
• thrombomodulin is capable of blocking thrombin's activation of another receptor, the prote- ase-activated receptor 1 (PAR-1 ) in cultured neuronal cells (Sarker, et al. Thromb. Haemost. (1999), 82: 1071-77).
• PAR-1 prote- ase-activated receptor 1
• Activated protein C has also been strongly implicated in the regulation of inflammatory responses involving various cytokines or activated leukocytes (Esmon et al., Thromb. Haemost. (1991 ), 66:160-165). Consistent with this hypothesis, studies have shown that activated protein C, by inhibiting the production of tumor necrosis factor (TNF-al- pha) prevents pulmonary vascular injury in rats administered endotoxin TNF-alpha is a potent activator of neutrophils (Murakami et al., Blood (1996), 87:642-647; Murakami et al., Am. J Physiol. (1996), 272:L197-2).
• the thrombolytic effect of thrombomodulin according to one embodiment of the invention regarding the improvement of reperfusion was surprisingly found in an animal model with a stable occlusion of the middle cerebral artery (MCA). Mice with an occluded MCA were treated with a soluble thrombomodulin and surprisingly exhibited a substantial reperfusion as measured by an increase cerebral blood flow (CBF). This finding was unexpected, since the anticoagulant effects known for thrombomodulin from animal studies were merely suggestive of an ability to prevent blood clotting, rather than to restore blood flow.
• the term “reperfusion” refers to any improvement of the blood flow compared to the state of occlusion, which can either be a partial or a total reperfusion.
• reperfusion is not limited to effects, which result in the complete restoration of the original blood flow before the ischemic event.
• the reperfusing effect of thrombomodulin is assumed to include effects which antagonize the thrombus formation and/or support the spontaneous lysis of blood clots.
• the term “occlusion” is defined as any stricture or narrowing of a blood vessel which results in a reduced blood flow of the tissue distal thereof compared to the healthy or normal blood vessel.
• the occlusion can either be partial or complete.
• the term occlusion encompasses also a stenosis, i.e. abnormal narrowing of a blood vessel still allowing distal perfusion.
• thrombomodulin can be used for preventing or at least lowering the risk of an occlusion of blood vessels by thromboembolic events, in particular by secondary thromboembolic events. These secondary thromboembolic events can be cerebral blood clots, deriving from the primary ischemic event.
• thrombomodulin can be used to treat stroke patients suffering from the risk of secondary cerebral vascular occlusions (reoc- clusions).
• SOLID was designed as a single-center, randomized, single-blind, placebo-controlled Phase I study in healthy volunteers.
• the SOLID-I study looked into possible negative effects of the applied Solulin doses on the clotting system.
• five groups of volunteers were each administered a single dose of Solulin, with escalating dosages in the consecutive dose groups. Each dose increase was first approved by the study safety committee.
• some of the study subjects received a pharmacologically inactive substance, i.e. a placebo.
• Solulin Within the chosen dose range of 0.6 to 30 mg, Solulin was shown to inhibit thrombin formation in a dose-dependent manner by up to 98%. Already in the lowest dose group an effect could be seen and a 50% inhibition of thrombin formation was achieved with 1 mg indicating the expected therapeutic doses.
• thrombomodulin combines in one molecule the diverse functional properties of an anticoagulant and a thrombolytic. Namely, like an anticoagulant thrombomodulin is able to prevent thrombotic events and like a thrombolytic thrombomodulin is able to induce or cause reperfusion. Therefore based on the inven- tion thrombomodulin is a first representative of a new class of "bi-functional" drugs exhibiting anticoagulant and thrombolytic properties.
• thrombomodulin in particular suitable for treating patients with a combination of a thrombotic risk and an existing or evolving thrombosis.
• minor strokes are treatable with thrombomodulin.
• a minor stroke represents a clinical exclusion criterion for a thrombolytic therapy due to an unfavorable risk benefit ratio. This is due to the consideration, that on one hand patients with minor stroke often have had a clot that is already resolved, and on the other hand the inherent bleeding risk of thrombolytics restricts the use of thrombolytics to the more severe stroke cases. Since these patients have a high risk for a subsequent thrombotic event, it is also described as "unstable stroke patients".
• thrombomodulin could be used to treat patients suffering a minor stroke or a stroke that has already improved by the time of the clinical assessment.
• an anticoagulant it can be used to prevent further thrombotic event and as a thrombolytic it can resolve the clot "in statu nascendi", in particular in cases where a clot has been formed despite thrombomodulin anticoagulation.
• thrombomodulin can be administered to the patient who is diagnosed with a minor stroke, and can be applied as a thrombolytic therapy for treating minor stroke.
• a minor stroke can be defined by a stroke severity of equal to or less than 6, preferably equal to or less than 4 on the National Institutes of Health Stroke Scale (NIHSS).
• minor stroke can be defined according to the 5 working definitions (definitions A-E) proposed by the National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group (Ann Emerg Med (2005); 46: 243-251).
• Definition A includes all patients who have scores of 0 or 1 on every baseline NIHSS score item, except level of consciousness (items 1a to 1c), which must be be 0. Maximum possible NIHSS score in this definition is 11.
• Definition B includes all presumed small-vessel occlusive patients. This definition is based on a lacunar-like syndrome.
• Definition C includes all patients with motor deficits (can include dysarthria or ataxia) with or without sensory deficits. These patients can have only a combination of motor, coordination, and sensory deficits without any deficits in the spheres of language, level of consciousness, extinction or neglect, horizontal eye movements, or visual fields, deficits generally ascribed to larger territories of focal ischemia.
• This definition attempts to capture those patients with the lacunar syndrome of pure motor hemiparesis or the related lacunar syndromes of sensorimotor stroke and ataxic hemiparesis.
• Definition D includes all patients with baseline NIHSS in the lowest (least severe) quar- tile of severity (NIHSS score ⁇ 9), excluding all patients with aphasia, extinction or neglect, or any points on the level-of-consciousness questions. This definition takes the least severe quartile of patients and further eliminates those with selected items that are generally not involved with smaller, more minor infarcts.
• Definition E includes all patients who are in the lowest quartile of stroke severity based on baseline NIHSS score (maximum NIHSS score 9). The definition analyzes the group of patients with the lowest quartile of NIHSS scores independent of the spheres of neurological deficit involved.
• the NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurological deficit.
• the NIHSS was originally designed as a research tool to measure baseline data on patients in acute stroke clinical trials.
• the scale is also widely used as a clinical assessment tool to evaluate acuity of stroke patients, determine appropriate treatment, and predict patient outcome.
• parameters such as the level of consciousness, the eye movement, the facial palsy or the motor ability of arms or legs are assessed and subject to a pre-defined numerical scoring.
• a NIHSS score of 6 to approximately 15 is qualified as a stroke of medium severity.
• a score of 15 or more of the NIHSS scale indicates a rather severe stroke.
• a stroke of a NIHSS score of 20 or more is considered as being untreatable.
• qualification of the severity of a stroke depends also on the individual assessment of the patient by the physician, which includes aspects of the overall clinical performance of the patient.
• a baseline NIHSS score of equal to or less than 6 is preferable.
• any imaging tool can be applied which results in the visualization of the inner opening of structures filled with blood ad therewith enables the identification of an arterial occlusion.
• Possible imaging modalities include MRI or CT and further developments or modifications thereto; however without being limited to it.
• the visualization of blood vessels can also be referred to as angiography.
• Various methods for the further evaluation of MRI or CT images are known to the person skilled in the art (e.g. MTT, TTP or Tmax as post processing maps).
• occlusion can be treated which are localized in a cerebral artery, in particular the middle cerebral artery (MCA), the anterior cerebral artery (ACA) and/or the posterior cerebral artery (PCA) including all of their branches, in particular M1 and/or M2.
• MCA middle cerebral artery
• ACA anterior cerebral artery
• PCA posterior cerebral artery
• thrombomodulin either as an anticoagulant or as a thrombolytic can be based on the diagnosis of the status of the blood vessels.
• the TIMI scale can be used.
• the TIMI scale (Thrombolysis in Myocardial infarction scale) was originally developed for the assessment of arterial occlusions in myocardial infarction and encompasses 4 grades as follows:
• grade 3 normal blood flow grade 2: artery entirely perfused but blood flow delayed grade 1 : artery penetrated by contrast material but no distal perfusion grade 0: complete occlusion of the vessel
• TIMI grade of 0 to 2 suffer from a complete or partial occlusion and can be (preferably acutely) treated with thrombomodulin based on its thrombolytic activity.
• thrombomodulin can however prevent (re-)occlusion and is given for acute prevention or chronically, e.g. for longer time periods from days to weeks as secondary prevention treatment.
• thrombomodulin can be used to treat patients suffering from a transient neurological attack.
• Transient neurological attacks are attacks with temporary ( ⁇ 24hours) neurological symptoms. These symptoms can be focal, nonfocal or a mixture of both. Due to a recent publication also patients who experience nonfocal TNAs, and especially those with mixed TNAs have a higher risk of further thrombotic events and are therefore especially suited for a anticoagulant therapy using thrombomodulin (Bos et al.,: Incidence and prognosis of transient neurological attacks. In: JAMA 2007, 298: 2877-2885).
• the anticoagulative treatment using thrombomodulin in patients suffering from TNA is preferred from about 1 day to about 3 months, however the preventive treatment can be initiated as soon as possible since the highest thrombotic risk was observed in the acute phase of the ischemic event.
• thrombomodulin can be used to treat patients suffering from a transitory ischemic attack (TIA). This is mainly based on its anticoagulative properties which enable a prevention of further occlusion. However if these TIA patients underwent a further thrombotic event the thrombodulin that is still present in the blood plasma can help to induce reperfusion. In his case it can be necessary to apply supplementary thrombomodulin or to increase the thrombomodulin dose. Hence according to the invention thrombomodulin can either be used as an anticoagulant or a thrombolytic to treat TIA patients.
• TIA transitory ischemic attack
• TIA is defined as a brief, reversible episode of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours and usually less than 1 hour, caused by a transient thrombotic or embolic blood vessel occlusion. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g. embolic vs. thrombotic). A recently proposed TIA definition also includes the absence of acute infarction.
• ICD-10 classification of the WHO TIA can be also described as impending cerebrovascular accident or intermittent cerebral ischemia and includes the following clinical syndromes: vertebrobasilar artery syndrome, carotid artery syndrome (hemispheric), multiple and bilateral precerebral artery syndromes, amaurosis fugax, transient amnesia (excluding amnesia NOS), other transient cerebral ischemic attacks and related syndromes and unspecified transient cerebral ischemic attack.
• the short-term stroke risk after TIA is higher than after major ischemic stroke, with recent studies showing that 4-20% will have a stroke within 90 days after a TIA, half within the first 2 days. Also, in patients with acute cerebral ischemic events (stroke or TIA), those with greater recovery in the first 24 hours have the greatest risk of occurrence.
• TIA In the recommendation for initial management of TIA, several clinical features support a timely hospital referral such as the case of of multiple and increasingly frequent symptoms (“crescendo TIAs"), duration of symptoms > 1 hour, a known hypercoagu- lable state, or an appropriate combination of the califomian score, the ABCD score or the ABCD 2 score (National Stroke Association guidelines for the management of TIA). Since these clinical features indicate an increased risk for a further thrombotic event they could be also taken as inclusion criteria for a thrombomodulin therapy.
• the general medical assessment of TIA includes an EKG, full blood count, serum electrolytes and creatinase and fasting blood glucose and lipids. This assessment should help to define the nature of the event and can be used to decide on a thrombomodulin therapy.
• CT computed tomography
• CTA computed tomography angiography
• MRI magnetic imaging resonance
• MRA magnetic resonance angiography
• Transcranial dopper is a complementary examination in patients with a recent TIA. It may provide additional information on patency of cerebral vessels, re- canalization and collerateral pathways. Every of the above mentioned brain imaging technologies taken alone or in combination can therefore be helpful to decide on a thrombomodulin therapy.
• thrombomodulin can be used as a thrombolytic or an anticoagulant for the treatment of non-cardioembolic or cardioembolic TIA/stroke.
• cardioembolic TIA/stroke The underlying mechanism of cardioembolic TIA/stroke is occlusion of cerebral vessels with debris from a cardiac source.
• An embolus may consist of platelet aggregates, thrombus, platelet-thrombi, cholesterol, calcium or bacteria. Most embolic debris contain platelet aggregates. However, no single mechanism is responsible for the development of cardiac emboli. The specific underlying cardiac disease determines the pathophysiology and natural history, and hence each cardioembolic source must be considered individually. Cardioembolic embolism accounts for approximately 20% of ischemic strokes each year. In general, cardioembolic strokes have a worse prognosis and produce larger and more disabling strokes than other ischemic stroke subtypes.
• cardioembolic TIA/stroke thrombomodulin may represent a promising therapeutical option since it inhibits directly and indirectly (via protein C) thrombin which is a potent platelet activator and plays a key role in the initiation of platelet thrombus as well as in the late platelet thrombus growth and/or stability.
• High-risk cardiac sources includes, but is not limited to, rheumatic mitral stenosis, prosthetic valves, infective endocarditis, nonbacterial thrombotic (marantic) endocarditis, ischemic heart diesease, acute myocardial infarction, left ventricular akinesis or aneurysm, nonischemic cardiomyopathies (e.g.
• idiopathic dilating viral myocarditis-associated, echinococcal, peripartum, amyloid-associated, hypereosinophilia syndrome-associated, rheumatic myocarditits-associated, sarcoidosis-related, neuromuscular disorder-associated, catecholamin-induced, doxorubicin-induced, mitoxantrone-related, crack-cocaine-related, cardiac oxalasis-associated), atrial fibrillation, atrial flutter, atrial myxoma or the sick-sinus syndrome (so called brachy-tachy syndrome).
• thrombomodulin is used in patients with an increased risk for a thrombotic event.
• This enhanced risk may be the consequence of a underlying disorder which includes, but is not limited to, stroke, diabetes, myocardial infarction, unstable angina, atrial fibrillation, renal damage, pulomary embolism, deep vein thrombosis and organ and prosthetic implants.
• Other risk factors are hypotension, hypercholesteremia, hyperlipidemia, cigarette smoking, alcohol consumption, obesity and low physical activity.
• the risk can be the result of clinical factors like age, blood pressure, microemboli, and biomarkers.
• Clinical factors can be used to establish a diagnostic score.
• the ABCD 2 score can predict the likelihood of a subsequent thrombotic event and is calculated as:
• Diabetes 1 point
• the total score is in a range of 0 to 7.
• the risk for a thrombotic event is low for a score of 0-3, moderate for a score of 4-5 and high for a score of 6-7.
• patients with an ABCD 2 of 3 or more, in particular of at least 4, more preferred of at least 6 are treated with thrombomodulin.
• the thrombotic risk may be assessed based on the genetic predisposition of the patient (e.g. Factor V Leiden, mutations or polymorphisms in the following genes: Cystatin C, type 4 collagen alpha-1 , prothrombin, phosphodiesterase 4D, ACE, Inter- leukin 1 -receptor antagonist, interleukin-6, 5-lipoxygenase activating protein (FLAP), arachidonate 5-lipoxygenase (Alox-5), toll-like receptor-4, mannose-binding lectin), the use of medications (e.g. contraceptives) or pathological changes of the vasculature including artherosclerosis, vasculitis and aneurysms.
• the genetic predisposition of the patient e.g. Factor V Leiden, mutations or polymorphisms in the following genes: Cystatin C, type 4 collagen alpha-1 , prothrombin, phosphodiesterase 4D, ACE, Inter- leukin 1
• thrombomodulin is used for the treatment of so called lacunar stroke.
• a lacunar stroke is defined as a small subcortical infarct (>15 mmm in diameter) in the territory of the deep penetrating arteries (diameter 0.2 -15mm). Lacunes occur most frequently in the basal ganglia and internal capsule, thalamus, corona radiata, and pons. Symptoms often occur in either a flucatuating (e.g. capsular warning syndrome) or a progressive manner. Patients that exhibits this course of disease are often diagnosed too late in order to receive a thrombolytic therapy with r-tPA. In turn these patients qualifiy for a thrombolytic therapy using thrombomodulin. In addition patients with lacunar stroke often show an early substantial improvement and hence thrombomodulin can be used as anticoagulant to prevent a subsequent thrombotic event.
• thrombomodulin in another embodiment of the invention can be used as an anticoagulant or thrombolytic to prevent re-occlusion or to induce reperfusion in cancer patients with the risk or suffering from a cancer induced or related thrombosis.
• Thrombomodulin therefore can be used for the prevention and/or treatment of Trousseau's syndrome.
• This use of thrombomodulin particularly applies to cancer patients with an increased thrombotic risk, e.g. lung, breast, colorectal and prostate cancer and malignant brain tumours and adenocarcinoma, including ovary, pancreas, colon, stomach, lung and kidney.
• Risk factors for thrombotic events in cancer patients include immobility, use of central venous access devices, hormonal therapy, chemotherapy and surgery.
• thrombomodulin can be administered to an ischemic patients (in particular stroke patients) with less or no substantial risk of deleterious effects, in particular bleeding, com- pared to patients untreated with thrombomodulin.
• ischemic patients in particular stroke patients
• com- pared in particular bleeding, com- pared to patients untreated with thrombomodulin.
• the thrombomodulin is administered to the patient within the acute or early phase of the ischemic event.
• the administration is applied in the time window of the first 24 hours after the administration of a thrombolytic substance, for example tPA or any other plasminogen activating factor.
• thrombomodulin preferably is administered as an anticoagulant.
• the thrombomodulin as administered for anticoagulation within three hours after the onset of the ischemic event.
• the thrombomodulin is administered to the patients in a dosage, which does not substantially increase the blood coagulation parameters, as measured for example by an APTT or PTT assay known to the skilled person in the art.
• the APTT Activated Partial Thromboplastin Time
• PTT Partial Thromboplastin Time
• a dosage of thrombomodulin is administered to the patient, which is not associated with a prolonged coagulation time.
• the APTT values of healthy humans lie normally between around 25 sec. and 39 sec. Values outside this range are generally considered as abnormal.
• the applied dosage does not substantially prolong the APTT, but effectively prevents vessel occlusion as measured e.g. in the assay of photothrombotic occlusion of the middle cerebral artery in the mouse.
• the preferred dosage of thrombomodulin according to the invention is approximately 0.01 to 5 mg/kg body weight, preferably 0.03 to 3 mg/kg body weight, most preferred 0.03 to 1.5 mg/kg body weight or 0.05 to 1.0 mg/kg body weight.
• a possible dosage unit form such as a vial or ampoule, is suggested containing around 0.8 to 400 mg, preferred 2.4 to 240 mg, most preferred 0.8 to 1200 mg or 4 to 80 mg (assuming a patient of around 65 kg body weight).
• the dose range of thrombomodulin, in particular Solulin, for treating stroke, preventing coagulation and re-occlusion or thrombolytic therapy is approximately from 0.5 (in particular 0.6) to approximately 30 mg per patient and a more preferred dose range is 1 to 10 mg, most preferred 3 to 10 mg per patient.
• a ready-to-use pharmaceutical composition with a fixed thrombomodulin dose is provided.
• Thrombomodulin in particular Solulin
• Thrombomodulin preferably is given non-orally e.g. by intravenous application.
• An intravenous bolus application is possible.
• a pharmaceutical composition is provided containing thrombomodulin, in particular Solulin, in a doses in the range of 1-30 mg or more, preferably a fixed dose of 1 , 2, 2.5, 3, 4, 5, 6, 7, 7.5, 8, 9 or 10 mg of thrombomodulin, in particular Solulin.
• thrombomodulin can be administered either in a single dose or a multiple dose or a combination thereof. Doses as above, either body weight adjusted or fixed doses can ne used.
• the single dose groups as well as the multiple dose groups showed that the administration of thrombomodulin (in particular Solulin) did not result in an antibody production against thrombomodulin within the volunteer.
• thrombomodulin in particular Solulin
• a multiple administration of thrombomodulin, in particular Solulin is possible for a long lasting period, i.e. an administration over weeks, months or years.
• a chronic thrombomodulin therapy is possible.
• this lack of immunogenicity allows that patients can receive more than therapy with thrombomodulin (in particular Solulin) in their lifetime.
• thrombomodulin in the context of the present invention is defined as any protein, including thrombomodulin modifications, analogues, variants, fragments and derivatives thereof, substantially showing the biological activity of native thrombomodulin regarding the capacity to form a functional complex with thrombin (all commonly referred to herein as thrombomodulin).
• thrombomodulin a "functional complex" with thrombin is any complex, which activates the protein C / protein S pathway.
• soluble thrombomodulin are known to the skilled person, e.g.
• Solulin is a soluble, as well as protease and oxidation-resistant analogue of human thrombomodulin and thus exhibits a long life in vivo.
• Solulin's main feature lies in its broad mechanism of action since it not exclusively inhibits thrombin. It also activates the natural protein C / protein S pathway, and therefore stops further generation of thrombin.
• Solulin exerts a neuroprotective effect (see e.g. EP 1 365 788), since binding of Solulin to thrombin prevents the latter from activating its Protease Acti- vatable Receptors (PARs). Inhibition of PAR receptors in turn blocks apoptotic cell death.
• PARs Protease Acti- vatable Receptors
• Solulin is inter alia subject of the European patent 0 641 215 B1 , EP 0 544 826 B1 as well as EP 0 527 821 B1.
• Solulin is administered to the patient.
• Solulin contains modifications compared to the sequence of native human thrombomodulin (SEQ. ID NO. 1 ) at the following positions: G -3V, Removal of amino acids 1-3, M388L, R456G, H457Q, S474A and termination at P490.
• This numbering system is in accordance with the native thrombomodulin of SEQ. ID NO. 1.
• the sequence of Solulin as the preferred embodiment of the invention is shown in SEQ. ID NO. 2.
• thrombomodulin analogues can be utilized, which comprise only one or more of the above mentioned properties, or of the properties outlined in the above mentioned European patent documents EP 0 544 826 B1 , EP 0 641 215 B1 and EP 0 527 821 B1.
• the thrombomodulin analogue known from the WO 01/98352 A2 or US 6,632,791 can be used.
• rabbit derived thrombomodulin can be used.
• the 6EGF fragment of Solulin is an example of a thrombomodulin fragment with essentially the same biological activity regarding the formation of a complex with thrombin with the ability to activate human protein C. This fragment essentially consists of the six epithermal growth factors domain of native thrombomodulin.
• mice were anesthetized with 90mg/kg intraperitoneal chloral hydrate Morton Grove Pharmaceutical Morton Grove, IL) and then placed securely under a dissecting microscope (Nikon SMZ-2T, Mager Scientific, Inc.). After exposing the left middle cerebral artery (MCA), a laser Doppler flow probe (Type N (18 gauge), Transonic Systems) was attached to the surface of the exposed skull over the cerebral cortex located 1.5 mm dorsal median from the bifurcation of MCA. The probe was connected to a flowmeter (Transonic model BLF21) and records were made using a continuous data acquisition program (Windaq, DATAQ Instruments).
• a 1.5 mW green light laser (540 nm, Melles Griot) was directed at the MCA from a distance of 6 cm and Rose Bengal (Fisher Scientific) diluted to 10 mg/mL in PBS was then injected into the tail vein with the final dose of 50 mg/kg. The laser was then continued for 10 minutes after occlusion.
• the tissue perfusion rate of the cerebral cortex was monitored continuously with the laser doppler flow meter and recorded for approximately 2-3 hours. Stable occlusion was achieved if the tissue perfusion rate was reduced by 70 % or more of its original value.
• rats received bolus injections of Solulin (1 or 3 mg/kg) or vehicle in equal volumes (100 ⁇ l/kg). The time to thrombus formation was assessed by Laser Doppler measurement. The laser measurements were continued for at least 150 min after injection of Solulin or vehicle. The experiments were terminated approximately 2 hours after Solulin or vehicle administration by sacrificing the surviving animals
• Tissue perfusion units were recorded using DATAQ Instruments Win DAQ Serial Acquisition.
• Time needed for occlusion was calculated as the time between injection of Bengal red and stable occlusion. The latter was assumed when a 70% or higher reduction of blood flow had prevailed for 5 min. Times were read directly off the tracing and converted to number format.
• Blood flow data was compressed ( ⁇ 20 points per second) and saved as a CSV file. Raw data was graphed and irregular points were deleted. The flow data was normalized to a percentage using the average TPU value from 10 minutes before Rose Bengal injection to the injection. Area under the curve was calculated from the normalized flow from the Rose Bengal injection to 120 minutes using GraphPad Prism. In cases in which blood flow data became unavailable for technical reasons or death of the animal, a value of zero was assumed from that time point on.
• Solulin was generally well tolerated at either dose level. Fatalities after arterial occlusion in the control and the low and high dose Solulin groups were 0/12, 0/10, and 1/10 animals, respectively
• Time courses of blood flow in the middle cerebral artery are shown in Figures 1-3. Traces are shown after normalization to a percentage based on the TPU value averaged from 10 minutes before Rose Bengal injection to the injection. The time to occlusion as indicated by the drop of blood flow was prolonged in Solulin-treated animals compared to control mice. More striking, the occlusion remained stable in control experiments (except for one technical perturbation, see legend to Figure 1) while it was transient in most Solulin-treated animals (4/10 and 6/10 animals at 1 and 3 mg/kg Solulin, respectively).
• Figure 4 summarizes the time needed for occlusion. Solulin at either dose significantly prolonged the time to occlusion compared to controls. (The P values of 1 mg/kg and 3 mg/kg versus control are 0.01 and 0.005, respectively. Shown are mean ⁇ SEM of 10- 12 animals per group).
• Rose Bengal was injected into the tail vein (time 0 in the diagram) to induce thrombus formation and subsequent occlusion at the site of laser irradiation. Animals 5 and 6 died shortly after the Rose Bengal injection and were not included in this data analysis.
• the temporary increase in the tracing of one animal may be related to insufficient anaesthesia resulting in movement of the animal relative to the laser flow probe. However, this temporary increase, regardless of its cause, was still included in the analysis.
• Fig. 2 Tissue perfusion downstream of the mouse middle cerebral artery after injection of Solulin at a dose of 1 mg/kg
• Rose Bengal was injected into the tail vein (time 0 in the diagram) to induce thrombus formation and subsequent occlusion at the site of laser irradiation.
• Rose Bengal was injected into the tail vein (time 0 in the diagram) to induce thrombus formation and subsequent occlusion at the site of laser irradiation.
• Animal 3 died shortly after the Rose Bengal injection and was not included in the analysis.
• control and Solulin were significant at either concentration designated by the single asterisk.
• the P values at 1 mg/kg and 3 mg/kg versus control are 0.010 and 0.005, respectively. Shown are mean ⁇ SEM of 10-12 animals per group.
• the difference between Solulin and controls was significant at either Solulin concentration and so was the difference between the 1 and 3 mg/kg Solulin doses.
• the P values of 1 mg/kg and 3 mg/kg versus control were 0.043 and 0.001 , respectively.
• the P value of 1 mg/kg versus 3 mg/kg was 0.040.
• Data are presented in relative units representing the area under the curve of the blood-flow time chart per 120 min observation interval. Shown are mean values ⁇ SEM of 9-12 animals per group.
• Photothrombotic Model of Ischemic Stroke Thrombomodulin Added after Arterial Occlusion Using a model of photothrombotic occlusion of the middle cerebral artery the ability of soluble thrombomodulin (Solulin) to interfere with thrombosis was tested. The drug was added after occlusion of the middle cerebral artery.
• Solulin soluble thrombomodulin
• mice C57BL/6 strain.
• the age of the animals at the start of testing was approximately 12 weeks.
• mice were anesthetized with 90 mg/kg intraperitoneal chloral hydrate (Morton Grove Pharmaceutical Morton Grove, IL) and then placed securely under a dissecting microscope (Nikon SMZ-2T, Mager Scientific, Inc.). After exposing the left middle cerebral artery (MCA), a laser Doppler flow probe (Type N (18 gauge), Transonic Systems) was attached to the surface of the exposed skull over the cerebral cortex located 1.5 mm dorsal median from the bifurcation of MCA. The probe was connected to a flowmeter (Transonic model BLF21 ) and recorded with a continuous data acquisition program (Windaq, DATAQ Instruments).
• MCA left middle cerebral artery
• a 1.5 mW green light laser (540 nm, Melles Griot) was directed at the MCA from a distance of 6 cm and Rose Bengal (Fisher Scientific) diluted to 10 mg/mL in PBS was then injected into the tail vein with the final dose of 50 mg/kg. The laser was then continued for 10 minutes after occlusion.
• the tissue perfusion rate of the cerebral cortex was monitored continuously with the laser doppler flow meter and recorded for approximately 2-3 hours. Stable occlusion was achieved if the tissue perfusion rate was reduced by 70% or more of its original value.
• treatment with the test substances was initiated and the cerebral blood flow (CBF) was continuously measured for up to 2 hours.
• CBF cerebral blood flow
• a bolus injection of Solulin 100 ⁇ l was administered via the tail vein 30 minutes after a stable MCA occlusion has been verified (ischemic stroke). After stroke, further Solulin injections were performed at 24 hour intervals to a total of three. Animals were euthanized 72 hours post-stroke.
• Fig. 7 shows the CBF at 72 hours post-stroke. (Solulin a 1 mg/kg; Additional doses on day 2 and day 3).
• the acute anti-thrombotic efficacy of Solulin doses was studied in a rat model of thromboplastin-induced venous stasis, together with two comparators: activated protein C (APC), using the commercially available drug, Xigris® (Drotrecogin alfa activated), and the low molecular weight heparin, Enoxaparin.
• APC activated protein C
• the vena cava was prepared in anaesthetized male Sprague-Dawley rats and two loose ligatures were made on the vena cava between the left renal and the iliac vein.
• Solulin, Enoxaparin or vehicle (0.9% NaCI) were i.v. administered 30 min before i.v. injection of 250 ⁇ g/kg thromboplastin.
• APC was i.v. applied 5 min before thromboplastin. Injected volumes were 5 ml/kg in each case.
• thromboplastin stasis was established by tightening the sutures.
• Table 1 Thrombus weights and Wessler score after Solulin, APC, Enoxaparin, or vehicle administration in a venous stasis model in rats.
• Solulin, Enoxaparin or vehicle were i.v. injected into anaesthetized male and female Sprague-Dawley rats 30 min before standardized transection of the tip (3 mm) of the tail.
• APC was i.v. administered 5 min prior to tail tip transection. All rats remained anesthetized during the observation period.
• Subaqueous bleeding time was determined in pre-warmed saline at 37 0 C by the length of time between vertical immersion of the tails into the test tube and bleeding cessation for at least 15 sec. Any incidences of re- bleeding were noted for up to 20 min thereafter. Prolongation of bleeding time by 50 % or more relative to the vehicle control group of animals was considered significant.
• APC significantly extended the bleeding time at 0.5 mg/kg in males and at 2 mg/kg in both genders. After administration of the 0.5 mg/kg dose, re-bleedings remained comparable to controls (20-40 %), but increased to 60 % in males and 80 % in females in the 2 mg/kg group.
• Table 2 Effects of various Solulin doses compared to APC and Enoxaparin on tail transection bleeding time in rats.
• APC significantly affected the bleeding time even at doses that were either barely (0.5 mg/kg) or moderately effective (2 mg/kg) in the rat stasis model of venous thrombosis is in agreement with the clinical profile of this drug and may be explained by a more general inhibition of thrombin generation.
• Solulin, Enoxaparin or vehicle (0.9% NaCI) were i.v. administered to male and female rats 30 min before blood collection from the inferior vena cava.
• APC was i.v. applied 5 min before blood collection from the same site.
• Citric platelet-poor plasma was prepared and tested for activated Partial Thromboplastin Time (aPTT), Prothrombin Time (PT) and Thrombin Time (TT).
• Table 3 Effects of various Solulin doses compared to APC and Enoxaparin on coagulation in vivo.
• Solulin and Enoxaparin dose-dependently influenced TT, leading to a maximal prolo- gation at the respective high doses. Effects were significant at 0.3 - 3 mg/kg Solulin and at both Enoxaparin doses corresponding to 1.5 -14.4-fold and 6.1 - 14.4-fold prolongations, respectively. In contrast, APC did not prolong TT in males and barely affected it in females (tab. 3).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Hematology (AREA)
• Vascular Medicine (AREA)
• Diabetes (AREA)
• Urology & Nephrology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Epidemiology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (1)

Applications Claiming Priority (5)

Publications (1)

Family

ID=40229136

Family Applications (1)

Country Status (5)

Families Citing this family (1)

Family Cites Families (7)

• 2008
  • 2008-06-27 AR ARP080102791A patent/AR067345A1/es unknown
  • 2008-07-04 CL CL2008001977A patent/CL2008001977A1/es unknown
  • 2008-07-10 EP EP08784685A patent/EP2175872A2/en not_active Withdrawn
  • 2008-07-10 JP JP2010515412A patent/JP2010532776A/ja not_active Withdrawn
  • 2008-07-10 WO PCT/EP2008/005623 patent/WO2009007112A2/en active Application Filing

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events